Human Papillomavirus

HPV Vaccines

The initial clinical trials for the HPV vaccine involved more than 20,000 women aged 16 to 26 from 33 countries. Trials showed that the vaccine is almost 100% effective in preventing abnormalities in cells in the cervix caused by high-risk HPV types 16 and 18. These abnormalities are a proven pre-cursor to cervical cancer. The HPV vaccine is recommended for preteen boys and girls at age 11 or 12 so they are protected before ever being exposed to the virus. HPV vaccine also produces the most infection-fighting cells, or antibodies, during the preteen years. Risks and hypersensitivity to HPV vaccines.  Therapeutic vaccines can be used to treat established HPV infections and could therefore have an immediate effect on the prevalence of HPV-associated malignancies. Therapeutic vaccine strategies aim to eliminate pre-existing lesions and even malignant tumors by generating cell-mediated immunity against HPV-infected cells. Live-vector-based vaccines can be classified into: i) bacterial vectors, such as Salmonella typhimurium and Listeria monocytogenes; and ii) viral vectors, such as adenovirus (AdV) and vaccinia virus. The use of vector-based vaccines for the delivery of antigen to dendritic cells (DC) is an appealing strategy for HPV vaccination. An Edible human papilloma virus vaccine obtained by culturing a transformant of an avirulent fission yeast host, wherein the transformant carries a gene encoding an antigenic protein of human papilloma virus introduced therein and accumulates the expressed antigenic protein in it. Safety and Immunogenicity of the Quadrivalent Human Papillomavirus Vaccine in HPV.  Vaccines storage and handling safety measures. A major step forward in helping protect millions of people in developing countries against HPV and cervical cancer.